SELECTED ORAL COMMUNICATION SESSION, SESSION 34: EARLY PREGNANCY LOSS PROGNOSIS AND TREATMENT, Tuesday 5 July 2011 10:00 – 11:30

Introduction: Multiple trials of immunotherapy for reproductive failure have failed to demonstrate significant benefit. A reason for this may be the lack of a test that selects which women will benefit from treatment. High density of uterine naturak killer (uNK) cells has been associated with recurrent miscarriage(RM) and prednisolonewas shown to reduce this uNK cell density. Hence we carried out a double blind randomised placebo controlled trial of prednisoloneversus placebo in early pregnancy for women with RM and increased uNK cell density. The aim of this pilot trial was to assess the feasibility of recruitment, integrity of trial procedures and potential efficacy for future power calculations.